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Abstract
In an aging society, Alzheimer’s disease (AD) exerts an increasingly serious health and economic burden. Current
treatments provide inadequate symptomatic relief as several distinct pathological processes are thought to underlie
the decline of cognitive and neural function seen in AD. This suggests that the efficacy of treatment requires a
multitargeted approach. In this context, palmitoylethanolamide (PEA) provides a novel potential adjunct therapy that
can be incorporated into a multitargeted treatment strategy. We used young (6-month-old) and adult (12-month-old)
3×Tg-AD mice that received ultramicronized PEA (um-PEA) for 3 months via a subcutaneous delivery system. Mice
were tested with a range of cognitive and noncognitive tasks, scanned with magnetic resonance imaging/magnetic
resonance spectroscopy (MRI/MRS), and neurochemical release was assessed by microdialysis. Potential
neuropathological mechanisms were assessed postmortem by western blot, reverse transcription–polymerase chain
reaction (RT-PCR), and immunofluorescence. Our data demonstrate that um-PEA improves learning and memory, and
ameliorates both the depressive and anhedonia-like phenotype of 3×Tg-AD mice. Moreover, it reduces Aβ formation,
the phosphorylation of tau proteins, and promotes neuronal survival in the CA1 subregion of the hippocampus.
Finally, um-PEA normalizes astrocytic function, rebalances glutamatergic transmission, and restrains
neuroinflammation. The efficacy of um-PEA is particularly potent in younger mice, suggesting its potential as an early
treatment. These data demonstrate that um-PEA is a novel and effective promising treatment for AD with the potential
to be integrated into a multitargeted treatment strategy in combination with other drugs. Um-PEA is already
registered for human use. This, in combination with our data, suggests the potential to rapidly proceed to clinical use.
Introduction
Alzheimer’s disease (AD) is the primary cause of
dementia in the elderly, but currently prescribed medi-
cations provide only modest and transient benefits to a
subset of patients.
Histopathologically, the major features of AD include
the extracellular accumulation of beta amyloid (Aβ) fibrils
in senile plaques (SPs) and intraneuronal neurofibrillary
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tangles (NFTs), whose precise role in the progression of
AD remains to be clarified1, 2. Interestingly, preclinical
and clinical data have demonstrated that both SPs and
NFTs are colocalized close to activated glial cells, sug-
gesting that a dysfunction in glia homeostasis is a key
pathogenetic mechanism in AD3–5. In the context of AD,
both astrocytes and microglia can be activated by Aβ
which promotes further reactive gliosis6. This phenom-
enon is normally engaged with the intent of defending the
brain by removing injurious stimuli (e.g., Aβ fibrils pha-
gocytosis). However, if prolonged, this response exceeds
normal physiological limits and can induce detrimental
effects7–10.
Our hypothesis is that an early combination of neuro-
protective and anti-inflammatory treatments represents a
promising treatment approach for the treatment of AD.
The endogenous lipid mediator palmitoylethanolamide
(PEA) demonstrates exceptional potential as a novel
treatment for AD. We have previously demonstrated PEA
anti-inflammatory and neuroprotective properties, as well
as its ability to preserve memory function in rodent
models of AD11–16. At present, we lack precise informa-
tion concerning both the effects of chronic PEA admin-
istration on the progression of AD and the optimal time
to begin treatment. This is an important consideration as
one of the major problems with the development of
effective treatments for AD is that diagnosis is normally
made at an advanced stage of the disease which may mean
many therapeutic interventions begin too late to be
effective.
In this paper, we evaluated the effects of chronic um-
PEA administration in 3×Tg-AD mice at two different
stages (mild and severe) of AD-like pathology and cog-
nitive deficits, by subcutaneously administering the drug
to two age groups of animals for 3 months. 3×Tg-AD
mice were chosen because they present both Aβ deposits
and tau pathology, as well as synaptic dysfunction, thus
representing a widely used and validated model which
closely mimics the neuropathological alterations seen in
human AD17, 18. The animals were then tested using a
range of cognitive and noncognitive tasks, followed by an
assessment of neuropathology.
Our data demonstrate the first in vivo evidence
that chronic treatment with ultramicronized-PEA
(um-PEA), a formulation which maximizes its bioavail-
ability19, 20, induces considerable improvements in
cognitive and neural function during both the early
presymptomatic and later symptomatic stages of
AD in a triple transgenic mouse model of AD (3×Tg-AD
mice).
Our data suggest that PEA demonstrates exceptional
potential as a novel treatment for AD and in combination
with the fact that is already licensed for the use in
humans, where it demonstrates high safety and
tolerability, provides an opportunity for its rapid transla-
tion in clinical pactice.
Materials and methods
Animals and pellet implantation
3×Tg-AD (harboring APPswe, PS1M146V, and tauP301L
transgenes) male mice and their sex- and age-matched
wild-type littermates (Non-Tg) (C57BL6/129SvJ) were
maintained in controlled conditions (12-h light/12-h dark
cycle, temperature 22 °C, humidity 50–60%, fresh food,
and water ad libitum). All procedures were conducted in
accordance with the guidelines of the Italian Ministry of
Health (D.L. 26/2014) and the European Parliamentary
directive 2010/63/EU.
Mice of 3 and 9 months were anesthetized by i.p.
injection of ketamine hydrochloride (1 mg/10 g) and
xylazine (0.1 mg/10 g). The area between the shoulder
blades was shaved and the surgical area was sterilized with
alcohol. A small (1–2 cm) dorsal midline incision was
made and a subcutaneous pocket was created with a blunt
probe. An um-PEA or a placebo pellet was placed into the
pocket and the incision was closed with sterile sutures.
Drugs and protocols
Um-PEA (EPT2110/1) was obtained from Epitech
group (Saccolongo, Italy). A 90-day-release pellet con-
taining either 28mg of um-PEA (Innovative Research of
America, Sarasota, Florida; cat. #NX-999) or placebo (cat.
#NC-111) was subcutaneously implanted. During pellet
inclusion process, um-PEA was homogeneously dis-
tributed in the matrix, maintaining its original crystalline
form and micrometric size; both dosage and administra-
tion route were chosen according to previous data20, 21.
Both Non-Tg and 3×Tg-AD mice were randomly
assigned to either placebo or um-PEA group. No animals
were excluded from the analysis. Behavioral sample size
(N) is specified in open and black bars of Fig. 1. For
molecular analyses, the sample size (N) for all experi-
mental groups/condition is specified in the figure legends.
Behavioral, microdialysis/HPLC, and MRI/MSI experi-
ments were performed as previously described22–29, and
conducted at the end of 90-day treatment. Mice were then
killed, and hippocampi were isolated for western blot
(WB), cytokine assays, and RT-PCR analyses, whereas
whole brains for immunohistochemistry were flash-frozen
in 2-methylbutane. Biochemical analyses were performed
as previously described12. The timeline of the experiments
is described in Fig. 1a.
Behavioral tests
The minimum interval between two consecutives pro-
cedures was 2 days. All tests were performed between 8:00
a.m. and 3:00 p.m., in a dimly lit condition. On the day of
testing, the mice were acclimated for about 60min in the
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behavioral room before the procedures were initiated.
Mice were weighed every day during the entire period of
the experiment. All behavioral tasks were analyzed by a
blinded investigator.
Novel object recognition test (NORT)
Each mouse was habituated to an empty Plexiglas arena
(45× 25× 20 cm) for 3 consecutive days. On training
(day 4), mice were exposed to two identical objects (A+A)
placed at opposite ends of the arena for 5 min. After 30
min and 24 h, the animals were subjected to a 5-min
retention session where they were exposed to one object
A and to a novel object B (after 30 min) and object C
(after 24 h). Exploration was considered as pointing the
head toward an object at a distance of <2.5 cm from the
object, with its neck extended and vibrissae moving.
Turning around, chewing, and sitting on the objects were
not considered exploratory behaviors. Behavior was
recorded with a MV750i camera (1024× 768 resolution,
Canon, Tokyo, Japan) and scored by a blinded investi-
gator. Videotapes were analyzed as MPEG files using a
behavioral tracking system furnished with infrared
lighting-sensitive CCD cameras. Animal performances
were monitored with the EthoVision XT version 7 video-
tracking software system (Noldus Information Technol-
ogy Inc., Leesburg, VA). The time of exploration was
recorded, and an object recognition index (ORI) was
calculated, such that ORI= (TN−TF)/(TN+TF), where
TN and TF represent times of exploring the familiar and
novel object, respectively. Mice that did not explore both
objects during training were discarded from further
analysis.
Inhibitory passive avoidance (IA)
On training, mice were placed in the fear-conditioning
chamber and were allowed to explore for 2 min before
receiving three electric foot shocks (1 s, 0.1 mA; inter-
shock interval, 2 min). Animals were returned to the
home cage 30 s after the last footshock. The animals were
subsequently tested 24 h or 7 days after the training phase
to assess the short- and long-term memory. During this
phase, the behavior in the conditioning chamber was
video recorded for 5 min and subsequently was analyzed
for freezing behavior, which was defined as the absence of
all movements except for respiration.
Morris water maze (MWM)
The test was conducted in a circular tank of 1.2 m in
diameter, and locates in a room with several extra maze
cues. Mice were trained to swim to a 14-cm-diameter
circular Plexiglas platform submerged 1.5 cm beneath the
surface of water and invisible to the mouse while swim-
ming. The water temperature was kept at 25 °C
throughout the duration of the test. The platform was
fixed in place, equidistant from the center of the tank and
its walls. Mice were subjected to four training trials
per day and were alternated among four random starting
points for 5 consecutive days. Mice were allowed to find
and escape onto the submerged platform. If the mice
failed to find the platform within 60 s, they were manually
guided to the platform and were allowed to remain on it
for 10 s. After this, each mouse was placed into a holding
cage under a warming lamp for 25 s until the start of the
next trial. Retention of the spatial memory (the probe
trial) was assessed 1.5 and 24 h after the last training
session and consisted of a 60 s trial without the platform.
Mice were monitored by a camera mounted in the ceiling
directly above the pool, and all trials were stored on
videotape for subsequent analysis. The parameters mea-
sured during the probe trial included initial latency to
cross the platform location, number of platform location
crosses, and time spent in the target quadrant.
Tail suspension test (TST)
Mice were suspended for 6 min by the tail and the
duration of immobility was measured during the last 4
min.
Forced swim test (FST)
Mice were individually placed in a Plexiglas cylinder (20
cm diameter, 50 cm high) containing 20 cm of water (25 °
C). The experiment lasted for 6 min and the duration of
immobility was analyzed during the last 4 min.
Sucrose preference test (SPT)
Singularly caged mouse had free access to two drinking
bottles, the first filled with tap water, while the other with
(see figure on previous page)
Fig. 1 Um-PEA rescues early memory deficits and ameliorates the depressive-like phenotype in the 3×Tg-AD mice. (a) Schematic
representation of the experimental design. Evaluation of the (b–k) cognitive and (l–o) emotional phenotype of 6- and 12-month-old 3×Tg-AD and
age-matched Non-Tg mice chronically treated with placebo (open bars) or um-PEA (black bars). Short- and long-term memory of mice was evaluated
by (b, g) novel object recognition test (NORT), (c, h) inhibitory passive avoidance (IA), and (d–f, i–k) Morris water maze (MWM). Moreover, the
emotional phenotype of mice was evaluated by (l) tail suspension test (TST), (m) forced swim test (FST), and (n, o) sucrose preference test (SPT).
Sample size is indicated in the bars. The data are presented as means ± SEM. Statistical analysis was performed by two-way ANOVA followed by Tukey
multiple- comparison test (*p < 0.05; **p < 0.01; ***p < 0.001)
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a 2% sucrose solution. Before the test, there was a period
of adaptation that lasted for 48 h. The animals were then
deprived of food and liquids for 3 h. During the next 24 h,
free consumption of water and 2% sucrose solution took
place, in the presence of ad libitum food. Fluid intake was
measured afterward by weighing the drinking bottles. The
sucrose preference (%) was determined as follows: sucrose
solution intake (g)/total fluid intake (g)× 100.
Biochemical testing procedures
RNA isolation and RT-PCR
Total RNA from hemi-hippocampi homogenates was
extracted by using the NZY total RNA isolation kit
(NZYTech, Lisboa, Portugal) following the company’s
datasheet. The total RNA was measured by Nanodrop 1
000 spectrophotometer (Thermo Fisher Scientific, MD,
USA), so, 1 µg of RNA was reverse transcribed to obtain
cDNA by using oligo(dT) and random primers of the
first-strand cDNA synthesis kit (NZYTech, Lisboa, Por-
tugal). All PCRs were performed using supreme NZYTaq
DNA polymerase (NZYTech, Lisboa, Portugal) with spe-
cific primers (Sigma-Aldrich, Milan, Italy) for tumor
necrosis factor-α (TNF-α, forward primer 5′-CAGCC-
GATGGGTTGTACCTT-3′ and reverse primer 5′-
CCGGACTCCGCAAAGTCTAA-3′), interleukin-1β (IL-
1β, forward primer 5′-GGACCCCAAAA-
GATGAAGGGC-3′ and reverse primer 5′-GGAAAA-
GAAGGTGCTCATGTCC-3′), and IL-10 (forward primer
5′-GCCCTTTGCTATGGTGTCCT-3′ and reverse pri-
mer 5′-CTCTGAGCTGCTGCAGGAAT-3′). Glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH, forward
primer 5′-GCTACACTGAGGACCAGGTTGTC-3′ and
reverse primer 5′-CCATGTAGGCCATGAGGTCCAC-
3′) was used as reference gene.
Protein extraction and western blot analysis
Hemi-hippocampi were homogenized in ice-cold
hypotonic lysis buffer (50 mM Tris/HCl, pH 7.5, 150
mM NaCl, 1 mM ethylenediaminetetraacetic acid
(EDTA), 1% triton X-100, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 10 μg/ml aprotinin, and 0.1 mM leu-
peptin, all from Sigma-Aldrich, Milan, Italy) and incu-
bated for 40 min at +4 °C. Protein dephosphorylation was
avoided by adding a phosphatase inhibitor cocktail. The
homogenates were then centrifuged, cellular membranes
discarded, and the obtained supernatant was aliquoted
and stored at −80 °C. Bradford assay was performed to
calculate protein concentration. An equal amount of
proteins (50 μg) was resolved on 12% acrylamide SDS-
PAGE precast gels (Bio Rad Laboratories, Milan, Italy)
and transferred onto nitrocellulose membranes through a
semidry system (Bio Rad Laboratories, Milan, Italy).
Membranes were blocked for 1 h either with no-fat dry
milk or bovine serum albumin (BSA) powders in tris-
buffered saline–0.1% tween 20 (TBS-T) (Tecnochimica,
Rome, Italy).
Overnight incubation at +4 °C was performed with one
of the following primary antibodies: rabbit anti-amyloid
precursor protein (anti-APP 1:1 000, Cell Signaling,
Danvers, MA, USA), rabbit anti-β-secretase (anti-BACE1
1:1 000, Cell Signaling, Danvers, MA, USA), mouse anti-
β-amyloid (1:200, Millipore, Darmstad, Germany), rabbit
anti-Akt (1:500, Cell Signaling, Danvers, MA, USA), rabbit
anti-p[Thr308]Akt (1:5 000, Cell Signalling, Danvers, MA,
USA), rabbit anti-glycogen synthase kinase-3β (anti-Gsκ-
3β 1:1 000, Cell Signaling, Danvers, MA, USA), rabbit
anti-p[Ser9]GSκ-3β (1:1 000, Cell Signaling, Danvers, MA,
USA), rabbit anti-p[Ser396]tau (1:1 000, Thermo Fisher
Scientific, Waltham, MA, USA), mouse anti-microtubule-
associated protein 2 (anti-MAP2 1:250, Novus Biologicals,
Littleton, CO, USA), rabbit anti-S100B (1:1 000, Epi-
tomics, Burlingame, CA, USA), rabbit anti-glial fibrillary
acidic protein (anti-GFAP 1:25 000, Abcam, Cambridge,
UK), rabbit anti-p[Ser536]nuclear factor kappa-light-
chain enhancer of activated B cells (anti-p[Ser536]NF-
κB p65 1:2 000, Cell Signaling, Danvers, MA, USA), rabbit
anti-inducible nitric oxide synthase (anti-iNOS, 1:8 000,
Sigma-Aldrich, Milan, Italy), rabbit anti-glutamate trans-
porter GLT-1 (1:1 000, Tocris, Bristol, UK), and mouse
anti-glutamine synthetase clone GS-6 (1:1 000, Millipore,
Darmstad, Germany). Rabbit anti-β-actin (1:1 500, Santa
Cruz, Dallas, TX, USA) was used as loading control.
Membranes were incubated with a specific secondary
horseradish peroxidase (HRP)-conjugated antibody (HRP-
conjugated goat anti-rabbit IgG, 1:10 000–1:30 000; HRP-
conjugated goat anti-mouse, 1:10 000; all from Jackson
ImmunoResearch, Suffolk, UK) either in no-fat dry milk
or BSA TBS-T. Immunocomplexes were detected by an
enhanced chemiluminescence (ECL) kit (GE Healthcare
Life Sciences, Milan, Italy) and the signal obtained was
quantified by ImageJ software after densitometric scan-
ning of the X-ray films (GE Healthcare Life Sciences,
Milan, Italy).
Immunohistochemistry
Immunohistochemistry for GFAP and MAP2 was per-
formed on coronal slices (12 µm thickness) containing the
hippocampal regions, collected, and postfixed with 4%
paraformaldehyde in 0.1M phosphate buffer solution
(PBS) (Tecnochimica, Rome, Italy). Slices were incubated
with blocking solution and then incubated overnight in
blocking solution containing either rabbit anti-GFAP (1:1
000, Abcam, Cambridge, UK) or mouse anti-MAP2
(1:250, Novus Biologicals, Littleton, CO, USA). Sections
were incubated with the proper secondary antibody
(1:200, fluorescein-affinipure goat anti-rabbit IgG (H+L);
1:300–1:400, rhodamine-affinipure goat anti-mouse IgG
(H+L), Jackson ImmunoResearch, Suffolk, UK) and 4′,6-
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diamidino-2-phenylindole (DAPI 1:75 000, Sigma-
Aldrich, Milan, Italy) in BSA at room temperature.
Fluorescent signal was detected by an Eclipse E600
microscope (Nikon, Tokyo, Japan) using both Nikon Plan
10X/10.25 and Nikon Plan Fluor 20X/0.5 objectives.
Pictures were captured by a QImaging camera (Canada)
with NISelements BR 3.2 64-bit software with pixel
resolution of 1024× 1024.
Analysis was performed by ImageJ software and data
were expressed as a ratio of the difference between the
Table 1 Results from the statistical analysis of data obtained from the behavioral tests of 6- and 12-month-old mice
Behavioral tests Parameter Genotype (G) Treatment (T) Interaction G × T
6 month old
NORT Object recognition index––30 min F (1,38) = 0.377, n.s. F (1,38) = 1.389, n.s. F (1,38) = 6.406 p < 0.05
Object recognition index––24 h F (1,37) = 11.993, p < 0.01 F (1,37) = 2.617, n.s. F (1,37) = 9.214, p < 0.01
IA Latency to enter dark compartment—24 h F (1,33) = 16.499, p < 0.001 F (1,33) = 5.513, p < 0.05 F (1,33) = 15.951, p < 0.001
Latency to enter dark compartment—
7 days
F (1,34) = 21.239, p < 0.001 F (1,34) = 29.431, p < 0.001 F (1,34) = 10.556, p < 0.01
MWM Latency to cross platform location—1.5 h F (1,39) = 6.842, p < 0.05 F (1,39) = 6.481, p < 0.05 F (1,39) = 8.757, p < 0.01
Latency to cross platform location—24 h F (1,39) = 4.698, p < 0.05 F (1,39) = 4.325, p < 0.05 F (1,39) = 7.879, p < 0.01
Time in the target quadrant—1.5 h F (1,39) = 4.441, p < 0.05 F (1,39) = 4.474, p < 0.05 F (1,39) = 6.050, p < 0.05
Time in the target quadrant—24 h F (1,39) = 4.836, p < 0.05 F (1,39) = 3.812, n.s. F (1,39) = 4.994, p < 0.05
Number of platf location crosses—1.5 h F (1,39) = 4.835, p < 0.05 F (1,39) = 7.845, p < 0.01 F (1,39) = 5.634, p < 0.05
Number of platf location crosses—24 h F (1,39) = 3.454, n.s. F (1,39) = 3.660, n.s. F (1,39) = 4.633, p < 0.05
TST Immobility F (1,39) = 44.062, p < 0.001 F (1, 39) = 7.203, p < 0.05 F (1, 39) = 9.308, p < 0.01
FST Immobility F (1,39) = 28.558, p < 0.001 F (1, 39) = 5.473, p < 0.05 F (1, 39) = 11.442, p < 0.01
SPT Total fluid intake F (1,39) = 0.349, n.s. F (1,39) = 0.382, n.s. F (1,39) = 1.991, n.s.
Sucrose preference F (1,39) = 22.547, p < 0.001 F (1,39) = 3.608, n.s. F (1,39) = 8.933, p < 0.01
12 month old
NORT Object recognition index—30 min F (1,30) = 0.154, n.s. F (1,30) = 1.251, n.s. F (1,30) = 9.460, p < 0.01
Object recognition index—24 h F (1,31) = 9.310, p < 0.01 F (1,31) = 0.112, n.s. F (1,31) = 3.431, n.s.
IA Latency to enter dark compartment—24 h F (1,29) = 4.799, p < 0.05 F (1,29) = 0.261, n.s. F (1,29) = 2189, n.s.
Latency to enter dark compartment—
7 days
F (1,29) = 1653, n.s. F (1,29) = 0179, n.s. F (1,29) = 1723, n.s.
MWM Latency to cross platform location—1.5 h F (1,29) = 1273, n.s. F (1,29) = 3.760, n.s. F (1,29) = 4.326, p < 0.05
Latency to cross platform location—24 h F (1,29) = 5.725, p < 0.05 F (1,29) = 0.388, n.s. F (1,29) = 0.464, n.s.
Time in the target quadrant—1.5 h F (1,29) = 3.715, p = 0.065 F (1,29) = 3.022, p = 0.094 F (1,29) = 3.437, p = 0.07
Time in the target quadrant—24 h F (1,29) = 2.107,n.s F (1,29) = 1.303, n.s. F (1,29) = 1.277, n.s.
Number of platf location crosses—1.5 h F (1,29) = 1.783, n.s. F (1,29) = 1.030, n.s. F (1,29) = 6.303, p < 0.05
Number of platf location crosses—24 h F (1,29) = 4.474, p < 0.05 F (1,29) = 0.261, n.s. F (1,29) = 0.225. n.s.
TST Immobility F (1,28) = 11.873, p < 0.01 F (1,28) = 0.363, n.s. F (1,28) = 1.681, n.s.
FST Immobility F (1,29) = 39.686, p < 0.001 F (1,29) = 0.00321, n.s. F (1, 29) = 4.690, p < 0.05
SPT Total fluid intake F (1,29) = 2.638, n.s. F (1,29) = 0.0558, n.s. F (1,29) = 0.733, n.s.
Sucrose preference F (1,29) = 1.126, n.s. F (1,29) = 2.319, n.s. F (1,29) = 4.563, p < 0.05
Two-way analyses of variance (ANOVA) with genotype (3×Tg-AD vs Non-Tg) and treatment (um-PEA vs placebo) as between-subject factors (n = 10–12 per group).
Details are reported in the text
NORT novel object recognition test, IA inhibitory passive avoidance, MWM Morris water maze, TST tail suspension test, FST forced swim test, SPT sucrose preference
test
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mean of fluorescence signal and the background (ΔF), and
the non-immunoreactive regions (F0). To prevent any
change in the fluorescent signal due to artifacts, the gain
and time exposure were kept constant during all image
acquisitions.
Cytokine array
Hippocampal homogenates were analyzed for cytokines
presence using a mouse cytokine array panel A (R&D
Systems, Minneapolis). A total of 100 μg for each hippo-
campal lysate were processed following the manu-
facturer’s instructions.
In vivo microdialysis and HPLC analysis
In vivo microdialysis was performed in awake and freely
moving mice. Anesthetized mice were stereotaxically
implanted with a CMA/7 guide cannula with stylet (CMA
Microdialysis, Stockholm, Sweden) into the ventral hip-
pocampus (anterior–posterior, −3.0 mm; lateral, +3.0
mm; and ventral, −1.8 mm from bregma). Following a 2-
day recovery period, the CMA/7 probe was inserted and
dialyses were carried out perfusing the probe with Krebs-
Ringer phosphate (KRP) buffer at flow rate of 1 μl/min.
The constituents of the KRP buffer were (in mM) NaCl
145, KCl 2.7, MgCl2 1, CaCl2 2.4, and Na2HPO4 2, buf-
fered at pH 7.4. After a 2-h stabilization period, four
baseline samples were collected every 20min. Probe
position was verified histologically and glutamate was
quantified by HPLC coupled to fluorescence detection.
Magnetic resonance imaging (MRI)/magnetic resonance
spectroscopy (MRS)
Mice of 6 and 12 months undergo MRI and MRS
scanning to evaluate genotype- and treatment-induced
differences in brain metabolism. Animals were anesthe-
tized with 2.5–1.5% isoflurane (IsoFlo, Abbott SpA,
Berkshire, UK) in oxygen at flow rate of 1 l/min. MRI/
MRS experiments were conducted on a 4.7T Agilent
Inova preclinical system (Agilent Technologies Inc., Palo
Alto, CA, USA) equipped with a combination of volume
and surface coils (Rapid Biomedical GmbH, Rimpar,
Germany). Fast spin-echo sagittal anatomical images
(Repetition Time (TR)/Echo Time (TE)= 3200/60 ms,
13 slices of 0.8-mm thickness, Field of View (FOV) 20×
25mm2, matrix 256× 256, 2 averages, and scan time 12
min) were acquired for positioning of the voxel for MRS.
Single voxel localized 1H MR spectra (PRESS, TR/TE= 4
000/23ms, NS= 256) were collected from hippocampus
(volume 9.5 μl) according to a quantitative protocol,
which includes water T2 measurements and LCModel
fitting routine for spectral analysis29. We adopted the
spectral analysis which considers Glx as the combined
signal that mainly comes from glutamate plus glutamine
because, at field strength generally used in human MRS
studies, they have overlapping signals.
Statistical analysis
Sample size was determined on the basis of our previous
experiments and by using the software GPower. All data
were expressed as mean ± standard error of measurement
(SEM). Behavioral, biochemical, and MRI/MRS data were
analyzed by two-way analyses of variance (ANOVA) with
genotype (3×Tg-AD vs Non-Tg) and treatment (um-PEA
vs placebo) as between-subject factors. Tukey’s honestly
significant difference (HSD) test or Bonferroni’s test were
used for multiple post hoc comparisons when required.
The threshold for statistical significance was set at p<
0.05.
Data availability
The data that support the findings of this study are
available from the corresponding author upon reasonable
request.
Results
Behavioral tasks
Statistical details are reported in Table 1.
Um-PEA improves learning and memory in 6-month-old
3×Tg-AD mice
We tested the effects of um-PEA on both short- (30
min) and long-term (24 h) memory with a novel object
recognition test (NORT). Two-way ANOVA analysis
revealed significant changes in the time mice spent
exploring the new object across the four different groups.
At 30min, we found significant genotype-by-treatment
interaction effects, while no significant differences were
found for the main effects of genotype and treatment. Post
hoc comparisons showed a significant higher object
recognition index (ORI) for 3×Tg-AD mice treated with
um-PEA with respect to placebo-treated 3×Tg-AD mice
(Fig. 1b). Performing this trial 24 h later, we observed a
significant genotype and genotype-by-treatment interac-
tion effect of ORI in the exploration session among the
four groups. Post hoc analysis demonstrated that um-
PEA-treated 3×Tg-AD mice performed significantly bet-
ter than the placebo-treated 3×Tg-AD group, and indi-
cated that, at both time points, um-PEA had no effect on
the performance of Non-Tg mice (Fig. 1b).
Contextual learning and memory were then evaluated
by an inhibitory passive avoidance task (IA), and the
retention test was then conducted 24 h or 7 days after the
training trial to assess short- and long-term memory.
Statistical analysis indicated, at both time points, a sig-
nificant main effect of genotype, treatment, and genotype-
by-treatment interaction. Multiple post hoc comparisons
indicated that um-PEA-treated transgenic mice
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performed better than placebo-treated 3×Tg-AD mice,
and reached the same performance level of Non-Tg ani-
mals (Fig. 1c). This was not due to differences in or
enhanced sensitivity to the footshock, as all mice had
similar jump responses upon shock administration.
Spatial learning was measured by the Morris water maze
(MWM). Mice received four training trials/day for 5
consecutive days to locate the hidden platform. Statistics
demonstrated no difference in spatial memory during
5 days of training among all groups measured (data not
shown). To determine the effects of um-PEA on memory,
the platform was removed from the maze, and tests were
conducted 1.5 or 24 h following the last training trial to
independently assess both short- and long-term memory,
respectively. Um-PEA rescued the early spatial memory
deficits present in 6-month-old 3×Tg-AD mice, as indi-
cated by a significantly decreased latency to cross the
platform location of the 3×Tg-AD mice treated with um-
PEA compared to placebo-treated 3×Tg-AD (Fig. 1d).
Moreover, the number of platform location crosses, as
well as the time spent in the target quadrant were sig-
nificantly increased in um-PEA-treated 3×Tg-AD com-
pared to placebo-treated 3×Tg-AD mice. Multiple post
hoc comparisons showed that 3×Tg-AD mice treated
with um-PEA performed similarly to the Non-Tg mice in
all probe trials and at both time points. Finally, um-PEA
had no significant effects on learning or memory retention
in Non-Tg mice (Fig. 1e, f).
Overall, these data indicate that um-PEA treatment
rescues early learning and memory deficits in 6-month-
old 3×Tg-AD mice.
Um-PEA improves short-term learning and memory alone in
12-month-old 3×Tg-AD mice
Two-way ANOVA for the ORI at a time point of 30 min
(short memory) in 12-month-old mice revealed a sig-
nificant genotype-by-treatment interaction effect, while
no significant main effects of genotype and treatment
were found. Multiple post hoc comparisons showed a
significant higher ORI in um-PEA-treated 3×Tg-AD with
respect to placebo-treated 3×Tg-AD mice (Fig. 1g).
When the probe trial was performed 24 h after the
exploration session (long-term memory), we observed a
significant main effect of genotype only among the four
groups (Fig. 1g).
In 12-month-old mice, IA showed significant main
effects only for genotype 24 h after the training trial,
whereas at 7 days, no significant main effects were
observed (Fig. 1h).
The results from MWM in 12-month-old mice
demonstrated that no significant differences were
observed during 5 days of training among the four dif-
ferent groups (data not shown). When the probe trial was
performed 1.5 h after the last training session (short-term
memory), statistical analysis showed that um-PEA sig-
nificantly decreased the latency to cross the platform
location and increased the number of platform location
crosses in 3×Tg-AD compared to placebo-treated 3×Tg-
AD mice (Fig. 1i, j). Regarding the time spent in the target
quadrant at 1.5 h after the last training session, no sig-
nificant differences were observed among the four groups,
although um-PEA induced a trend toward an increase
(+43%) in the 3×Tg-AD compared to placebo-treated
3×Tg-AD mice (Fig. 1k). Moreover, when testing was
performed at 24 h after the last training session (long-
term memory), statistical analysis showed a significant
main effect of genotype alone for both latency to cross the
platform location and the number of platform location
crosses (Fig. 1i–k).
Overall, these data indicate that um-PEA improves the
short-term memory of 12-month-old 3×Tg-AD mice,
with no significant effects on long-term memory. More-
over, um-PEA exerts no significant effects on learning or
memory in aged Non-Tg mice.
Um-PEA ameliorates the depressive- and anhedonia-like
behaviors in 3×Tg-AD mice
Depressive-like behaviors were measured by the tail
suspension test (TST) and forced swim test (FST). At
6 months of age, significant main effects of treatment,
genotype, and genotype-by-treatment interactions
were observed. Post hoc comparisons revealed that the
immobility time in both tests was higher in placebo-
treated 3×Tg-AD than in placebo-treated Non-Tg mice.
Moreover, um-PEA significantly decreased the immobility
time in the 3×Tg-AD for both tests (Fig. 1l, m). Inter-
estingly, we found a significant main effect of genotype
alone in 12-month-old mice, with no significant main
effects of treatment and genotype-by-treatment interac-
tion (Fig. 1l, m).
(see figure on previous page)
Fig. 2 Um-PEA effects on AD pathology. Evaluation of protein expression in hippocampi of 6- and 12-month-old 3×Tg-AD and age-matched Non-
Tg mice chronically treated with placebo (open bars) or um-PEA (black bars). (a) Representative western blots for APP, BACE1, and Aβ(1–42) proteins
and (b–d) densitometric analyses normalized to β-actin used as loading controls (N = 3, in triplicate). (e) Representative western blots for Akt, p
[Thr308]Akt, Gsκ-3β, p[Ser9]Gsκ-3β, p[Ser396]tau, and (f–j) densitometric analysis normalized to β-actin used as loading control (N = 3, in triplicate).
The results are expressed as percentage of control (Non-Tg/placebo groups). The data are presented as means ± SEM. Statistical analysis was
performed by two-way ANOVA followed by Bonferroni’s multiple-comparison test (*p < 0.05; **p < 0.01; ***p < 0.001)
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Anhedonia-like behaviors were measured by a sucrose
preference test (SPT). SPT revealed a significant main
effect of genotype and genotype-by-treatment interaction
at 6 months of age, and other significant main effects
included a genotype-by-treatment interaction at
12 months of age (Fig. 1n, o). Multiple post hoc com-
parisons demonstrated a significantly increased pre-
ference for sucrose in the placebo-treated Non-Tg mice
compared to placebo-treated 3×Tg-AD mice. Interest-
ingly, um-PEA restored the preference for the sweet
solution in the 3×Tg-AD group at both 6 and 12 months
of age. This effect was not accounted for by a difference in
total fluid intake among all groups (Fig. 1n, o).
Altogether, these results suggest that 3×Tg-AD mice
show a depressive-like phenotype that is reversed by um-
PEA treatment only at 6 months of age, while no sig-
nificant effect is observed at 12 months of age. Differently,
um-PEA treatment attenuates the anhedonia-like phe-
notype of both 6- and 12-month-old 3×Tg-AD mice.
Moreover, um-PEA has no significant effect on Non-Tg
mice.
Um-PEA reduces Aβ formation in aged 3×Tg-AD mice
To evaluate the effect of um-PEA on AD-like pathology,
we studied the expression of APP, BACE1, and Aβ(1–42).
Placebo-treated 3×Tg-AD mice of 6 and 12 months
compared with placebo-treated Non-Tg littermates
showed a significant increase of APP and, despite no
changes in BACE1 expression, exhibited a massive
increase in Aβ(1–42) levels. At both ages, um-PEA did not
change the expression of full-length APP. Interestingly,
um-PEA strongly reduced Aβ(1–42) expression in 3×Tg-
AD mice only at 12 months of age (Fig. 2a–d).
Together, these results show that chronic um-PEA
treatment reduces hippocampal Aβ(1–42) expression in
aging 12-month-old 3×Tg-AD mice, while inducing no
significant effects in younger 6-month-old 3×Tg-AD
mice.
Um-PEA reduces tau phosphorylation and promotes neuro-
nal survival in 3×Tg-AD mice
The expression of Gsκ-3β and the downstream abnor-
mally phosphorylated (p[Ser396]tau) tau protein, both
closely related to NFT formation and its associated
neuronal impairments, were evaluated30–34. We also
assessed the expression of the Akt, a kinase whose active
form p[Thr308]Akt is responsible for Gsκ-3β inactivation
through Ser9 phosphorylation35. The results showed,
despite no changes in the total Akt quantity, a significant
decrease of p[Thr308]Akt in 6-month-old placebo-treated
3×Tg-AD mice in comparison with placebo-treated Non-
Tg littermates. Although no differences in Gsκ-3β total
amount were detected, placebo-treated 3×Tg-AD
demonstrated a significant p[Ser9]Gsκ-3β reduction at
both ages compared to placebo-treated Non-Tg mice.
Um-PEA increased both p[Thr308]Akt and p[Ser9]Gsκ-
3β in 6-month-old 3×Tg-AD compared to age-matched
Non-Tg mice. Moreover, in placebo-treated 3×Tg-AD
mice at both ages, we observed a significant p[Ser396]tau
increase that was substantively reduced by um-PEA (Fig.
2e–j).
As a consequence of these observations, we investigated
neuronal survival by testing the expression of MAP2.
Western blot experiments did not show any difference
between expression in any of these groups at both ages
(Fig. 3d, e). However, immunofluorescence experiments,
which were performed to examine subtle differences in
expression between different hippocampal subregions,
revealed a significant increase in MAP2 immunoreactivity
in the CA1 of um-PEA-treated 3×Tg-AD mice at both
ages (Fig. 3a–c).
Altogether, these data suggest that um-PEA reduces
abnormal tau phosphorylation in the hippocampus of
3×Tg-AD mice at 6 and 12 months of age, and that such
an effect may be partially mediated by the Gsκ-3β/Akt
pathway. Moreover, um-PEA promotes MAP2 expression
and hence neuronal survival in the CA1 subregion of the
hippocampus of 3×Tg-AD mice.
Um-PEA normalizes astrocyte function and restrains
neuroinflammation
We examined the effects of chronic um-PEA treatment
on astrocyte function. Specifically, the expression of the
cytoskeletal GFAP and S100B, a glial-derived neuro-
trophin whose levels are affected in AD6, was tested. We
did not detect any significant difference in 6-month-old
3×Tg-AD mice compared to Non-Tg littermates in the
expression of both GFAP and S100B (Fig. 4a–d, f).
(see figure on previous page)
Fig. 3 Um-PEA effects on neuronal viability in hippocampus of 3×Tg-AD and Non-Tg mice. Evaluation of neuronal marker expression in
hippocampi of 6- and 12-month-old 3×Tg-AD and age-matched Non-Tg mice chronically treated with placebo (open bars) or um-PEA (black bars). (a,
b) Representative fluorescent photomicrographs of microtubule-associated protein 2 (MAP2) (red) staining in the CA1 region of hippocampi at both
6 and 12 months of age, and (c) fluorescence analysis expressed as ΔF/F0. Nuclei were stained with DAPI (blue) (N = 3, in triplicate). (d) Representative
western blots for MAP2 and (e) densitometric analyses normalized with β-actin used as loading controls (N = 3, in triplicate). The results are expressed
as percentage of control (Non-Tg/placebo groups). The data are presented as means ± SEM. Statistical analysis was performed by two-way ANOVA
followed by Bonferroni’s multiple-comparison test (*p < 0.05; p** < 0.01). Scale bar 100 µm
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We then examined the expression of a range of cyto-
kines which revealed that 3×Tg-AD mice exhibit a tran-
sition to an increased proinflammatory state. It is notable
that placebo-treated 6-month-old 3×Tg-AD mice dis-
played an increased transactivation of NF-κB p65 subunit,
an overproduction of proinflammatory mediators,
including iNOS, TNF-α, IL-1β, IL-16, and IL-5, macro-
phage colony-stimulating factor (M-CSF), monocyte
chemotactic protein 5 (MCP-5), and reduction of the anti-
inflammatory IL-10. Chronic treatment with um-PEA
almost completely abolished the increase in inflammatory
markers observed in 6-month-old 3×Tg-AD mice, and
suppressed the expression of p[Ser536]p65, IL-1β, M-CSF,
IL-16, MCP-5, and IL-5 but not iNOS and TNF-α, while
enhancing IL-10 transcription (Fig. 5).
Contrasting results were obtained in aging animals.
Indeed, placebo-treated 12-month-old 3×Tg-AD mice
exhibited a significant reduction of GFAP expression
compared to placebo-treated Non-Tg (Fig. 4a, b), and
immunofluorescence revealed that um-PEA restored
GFAP expression in the CA1 subregion of the hippo-
campus (Fig. 4e, f). Moreover, we did not observe any
genotype-related difference in S100B expression. Inter-
estingly, um-PEA significantly decreased S100B levels in
both genotypes (Fig. 4a, c). Finally, in 12-month-old mice,
we did not detect a transition to a proinflammatory state.
However, at this age, um-PEA reduced iNOS expression
in 3×Tg-AD, and enhanced IL-10 transcript in Non-Tg
(Fig. 5a, c, l, m).
Collectively, these results show that 6-month-old
3×Tg-AD mice exhibit mild astrocyte activation but
displayed an intense inflammatory status. In contrast,
12-month-old 3×Tg-AD mice did not demonstrate
astrocyte activation but a slight astrocyte atrophy not
accompanied by neuroinflammation. Um-PEA stabilizes
the altered parameters related to astrocyte function,
bringing them to more physiological levels, and restrains
neuroinflammation.
Um-PEA effect on glutamatergic transmission
Quantitative magnetic resonance spectroscopy (MRS)
analyses demonstrated that 6-month-old 3×Tg-AD mice
had reduced hippocampal levels of both Glx (a combined
measure of glutamate and glutamine) and N-acetyl-
aspartate (NAA) compared to age-matched Non-Tg lit-
termates. Interestingly, um-PEA significantly increased
Glx levels only in the 3×Tg-AD mice (Fig. 6a–d). As Glx
concentration reflects both intracellular and extracellular
glutamate and glutamine pools, we attempted to gain
deeper insights into the functional state of glutamatergic
transmission by microdialysis. The results showed that
basal extracellular glutamate levels in the hippocampus of
6-month-old 3×Tg-AD were significantly higher com-
pared to age-matched Non-Tg mice (Fig. 6e). Westren
blot analyses indicated that the higher extracellular glu-
tamate levels in transgenic mice may be partially due to
the reduced expression of GLT-1, while the expression of
GS remained unaffected (Fig. 6f–i). Even though our
results were not statistically significant, um-PEA treat-
ment induced a trend toward an increase of GLT-1
(+35%) in 6-month-old 3×Tg-AD mice compared to
placebo-treated Non-Tg ones (Fig. 6g, h).
In 12-month-old mice, we did not record any genotype-
related differences in Glx, NAA, or extracellular gluta-
mate levels despite a reduction in GLT-1 being evident
(Fig. 6).
Collectively, these results indicate that 6-month-old
3×Tg-AD mice exhibit a disruption to glutamatergic
function and that um-PEA increases Glx levels.
Discussion
This study, employing a multidisciplinary approach,
provides compelling evidence that a chronic um-PEA
treatment exerts anti-inflammatory and neuroprotective
effects in a murine model of AD that recapitulates the
salient neural and cognitive impairments seen in this
disease. It also demonstrates that um-PEA exerts these
effects in both mildly declining young (6-month-old) and
severely declining aging (12-month-old) 3×Tg-AD mice,
which suggests its potential to arrest the decline in neural
and cognitive function at two separate stages of the dis-
ease. These data also provide novel insights into the
molecular mechanisms involved in AD. We comprehen-
sively examined a number of pathways underlying astro-
cyte function, neuroinflammation, and neuronal integrity
in 6- and 12-month-old 3×Tg-AD mice chronically
receiving um-PEA or placebo for 3 months. Our results
confirm that important behavioral and molecular
(see figure on previous page)
Fig. 4 Um-PEA effects on astrocyte functionality in hippocampus of 3×Tg-AD and non-Tg mice. Evaluation of astrocytic markers in
hippocampi of 6- and 12-month-old 3×Tg-AD and age-matched Non-Tg mice chronically treated with placebo (open bars) or um-PEA (black bars).
(a) Representative western blots for GFAP and S100B proteins and (b, c) densitometric analyses normalized with β-actin used as loading controls.
Results are expressed as percentage of control (Non-Tg/placebo groups) (N = 3, in triplicate). (d, e) Representative fluorescent photomicrographs of
GFAP (green) staining in the CA1 subregion of hippocampi at both 6 and 12 months of age, and (f) fluorescence analysis expressed as ΔF/F0. Nuclei
were stained with DAPI (blue) (N = 3, in triplicate). The data are presented as means ± SEM. Statistical analysis was performed by two-way ANOVA
followed by Bonferroni’s multiple-comparison test (*p < 0.05). Scale bar 10 µm
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modifications occur during the early stages of AD, and
demonstrate that chronically administered um-PEA
restrains or reverses most of them.
These results are important as AD has important public
health and economic consequences and there is a need to
develop novel effective therapeutic strategies to comple-
ment or replace those in current use. It has been apparent
for a long time that PEA displays marked anti-
inflammatory properties in peripheral inflammation
models and it has demonstrated high effectiveness in a
number of neurodegenerative disorders that present with
an inflammatory component, including AD, Parkinson’s
disease, and multiple sclerosis10,14,36, 37. The recent
availability of um-PEA, a crystalline form on micrometric
size which improves both its pharmacokinetics and
bioavailability19, 38, prompted us to test its anti-
inflammatory and neuroprotective effects in 3×Tg-AD
mice.
First, we found that um-PEA rescued the early hippo-
campal, cortex, and amygdala-dependent memory
impairments seen in 3×Tg-AD mice. The youngest mice
(6-month old) demonstrated the largest significant
improvement of both short- and long-term memory. Less
clear-cut effects were seen in the oldest mice (12-month
old), where um-PEA improved short-term memory (or at
least some behavioral parameters, e.g., ORI, and latency
and number of crosses in the MWM), but did not induce
significant effects on long-term memory. This study also
demonstrates that um-PEA induces other noncognitive
effects that are relevant to AD. In this regard, following
the observation that a depressive-like phenotype is pre-
sent in the same strain of 18-month-old 3×Tg-AD
mice24, we identified that this phenotype is already pre-
sent by 6 months of age and is reversible at 6 but not at
12 months of age. However, we found that um-PEA
attenuates a similar anhedonia-like phenotype of both
young (6-month-old) and aging (12-month-old) 3×Tg-
AD mice.
It is widely accepted that glia mediate the response to
several brain injuries, including the deposition of Aβ, and
undergo important morphological and functional changes
that can, in turn, influence the progression of the disease.
These modifications are intricate and heterogeneous, and
can be crudely classified into hyperreactivity or atrophy39,
40. Moreover, a direct correlation has been established
between glial dysfunction and the induction of proin-
flammatory pathways41. In younger mice, although we did
not detect significant alterations of GFAP and S100B, the
best-known markers of astrocytic activation, we found
that a range of parameters suggesting an increase in
neuroinflammation occurred. These were reduced by um-
PEA, suggesting that it restrains the transition to a neu-
roinflammatory environment. A comparison of results
suggests that um-PEA effects are completely different in
3×Tg-AD mice at 6 and 12 months of age. At 12 months,
mice do not show any noteworthy signs of neuroin-
flammation and merely displayed moderate astrocyte
atrophy.
Based on our results and the hypothesis that neuroin-
flammation accelerates the development of the AD phe-
notype, increasing Aβ accumulation, we explored the
main elements involved in the pro-amyloidogenic path-
way42. 3×Tg-AD mice express a mutant APPswe trans-
gene, and we recorded an accumulation of this protein in
these mice at both 6 and 12 months. No accumulation of
BACE1 protein occurred, however, a 15-fold higher
increase in Aβ(1–42) expression was observed in the 3×Tg-
AD compared to Non-Tg mice. Our results demonstrated
the ability of um-PEA to strongly suppress Aβ(1–42)
expression in 12-month-old 3×Tg-AD mice, suggesting
an important pathway by which it can restrain the disease
progression. Another iconic hallmark of AD is the for-
mation of NFTs which are mainly caused by the abnormal
phosphorylation of tau. Tau protein is a microtubule-
associated protein that facilitates microtubule assembly
and stabilization as a function of its phosphorylation
state30. However, under pathological conditions, including
AD, enhanced phosphorylation (known as “hyperpho-
sphorylation”) occurs, which leads to microtubule dis-
sociation, aggregation into paired helical filaments, and
(see figure on previous page)
Fig. 5 Um-PEA effects on neuroinflammation in hippocampus of 3×Tg-AD and Non-Tg mice. Evaluation of proinflammatory markers in
hippocampi of 6- and 12-month-old 3×Tg-AD and age-matched Non-Tg mice chronically treated with placebo (open bars) or um-PEA (black bars).
(a) Representative western blots for p[Ser536]p65 and iNOS proteins and (b, c) densitometric analyses normalized with β-actin used as loading
controls. Results are expressed as percentage of control (Non-Tg/placebo groups) (N = 3, in triplicate). (d, e) Representative results obtained from RT-
PCR in 6-month-old mice for tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and (f, g) densitometric analysis of corresponding bands
normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Results are expressed as percentage of control (Non-Tg/placebo groups) (N
= 3, in triplicate). (h–k) Densitometric analysis of cytokine array for IL-16, IL-5, macrophage colony-stimulating factor (M-CSF), and monocyte
chemotactic protein 5 (MCP-5). Results are expressed as percentage of control (Non-Tg/placebo groups) (N = 3, in triplicate). (l) Representative results
obtained from RT-PCR in 6- and 12-month-old mice for IL-10 and (m) densitometric analysis of corresponding bands normalized with glyceraldehyde
3-phosphate dehydrogenase (GAPDH). Results are expressed as percentage of control (Non-Tg/placebo groups) (N = 3, in triplicate). The data are
presented as mean ± SEM. Statistical analysis was performed by two-way ANOVA followed by Bonferroni’s multiple-comparison test (*p < 0.05; **p <
0.01; ***p < 0.001)
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the subsequent production of insoluble NFTs43, 44. These
events worsen axonal transport and synaptic function,
which facilitates the development of a neurotoxic envir-
onment and cognitive impairments31, 32. Several kinases
add phosphate groups to tau-specific amino acids and
Gsκ-3β is one of the primary kinases that are involved30
and its activity is regulated by Akt, a serine/threonine-
specific kinase34. We observed significant alterations of
the Akt/Gsκ-3β pathway in 3×Tg-AD mice, at both mild
(6-month-old) and severe (12-month-old) stages of
pathology, and have also demonstrated for the first time in
an in vivo model the ability of um-PEA to prevent such
alterations, thus reducing the abnormal phosphorylation
of tau. Besides the deposition of NFTs, it has been
demonstrated that a disruption of astrocyte function
contributes to neuronal death39. In this study, we also
investigated the expression of the neuron-specific cytos-
keletal marker, MAP2. By immunofluorescence, we show
that um-PEA increases MAP2 expression in the CA1 zone
of the hippocampus in 3×Tg-AD mice at 6 and
12 months of age, suggesting that um-PEA increases
neuronal viability in this region, a key area for the med-
iation of memory formation and recall.
Alterations in both the glutamatergic system and the
metabolism of the brain are well documented in AD
patients45, 46. Employing both in vivo MRI/MRS scanning
and microdialysis sampling, we evaluated the effects of
um-PEA on neural metabolism and glutamatergic trans-
mission in the hippocampus of mice. MRI/MRS revealed
that 6-month-old 3×Tg-AD mice show a robust reduc-
tion of both Glx and NAA content compared to Non-Tg
mice. This observation may underlie the substantial cog-
nitive deficits observed at this age. Interestingly, um-PEA
increased Glx content and improved the cognitive per-
formance and behavioral abnormalities observed in
3×Tg-AD mice. Our data also highlight some intriguing
potential mechanisms by which AD affects glutaminergic
transmission. In younger (6-month-old) 3×Tg-AD mice,
we observed a marked increase in the levels of extra-
cellular glutamate, which is probably due to a reduced
expression of a glial transporter mainly responsible for
glutamate reuptake (GLT-1). Despite observing a similar
trend in aging (12-month-old) mice, we did not detect any
statistical difference in brain metabolites and extracellular
glutamate levels, but a reduction of GLT-1 expression was
still evident.
Our data extend the knowledge of the mechanisms
underlying the progression of AD-like pathology in
3×Tg-AD mice and demonstrate the exceptional ther-
apeutic potential of um-PEA in restraining the develop-
ment of AD-like pathology and cognitive/behavioral
declines by exerting a combination of anti-inflammatory
and neuroprotective effects. Given the numerous and
multitargeted effects of um-PEA that we observed, we can
speculate that many molecular mechanisms are involved
in mediating the actions of this compound. Despite we
have already demonstrated, in other preclinical models of
AD, that PEA exerts its pharmacological effects through
the peroxisome proliferator-activated receptors alpha
(PPARα) involvement11–13, 47, other molecular targets
should be taken into account, including PPARγ, transient
receptor potential vanilloid type-1 channel, orphan G-
protein-coupled receptor 55, and the so-called entourage
effect on the endocannabinoid system19. Therefore, fur-
ther experiments will be needed to address this issue. Our
results indicate an interesting interaction of um-PEA
treatment and the aging process, which may suggest its
use as a potential preventive therapy. In aging mice, um-
PEA treatment induces an effect on pathways involved in
AD pathology, but the most interesting data were derived
from younger mice. Indeed, changes in neural function in
mice precociously treated with um-PEA (starting from
3 months of age, before any overt signs of disease) seemed
to be less pronounced, suggesting the benefits of starting
drug treatment at an early stage.
From the perspective of the translational potential of
um-PEA in human AD, our data strongly suggest its
exceptional potential as a therapy that provides clinically
considerable benefits if started early enough in the con-
tinuum toward dementia. It is noteworthy that PEA,
(see figure on previous page)
Fig. 6 Um-PEA effects on brain metabolism and the glutamatergic system. Evaluation of the glutamatergic system in hippocampi of 6- and 12-
month-old 3×Tg-AD and age-matched Non-Tg mice chronically treated with placebo (open bars) or um-PEA (black bars). (a) MRI panel—Example of
in vivo fast spin-echo sagittal anatomical images (Repetition Time (TR)/Echo Time (TE) = 3200/60ms, consecutive slices). Voxels localized on
hippocampus are indicated by the white rectangles. (b) MRS panel—Examples of in vivo 1 H spectra (PRESS, TR/TE = 4000/23 ms, NS = 256).
Metabolite assignments: inositol (Ins), total creatine (tCr), glutamine + glutamate (Glx), taurine (Tau), total choline (tCho), N-acetyl-aspartate (NAA), N-
acetyl-aspartyl-glutamate (NAAG), and macromolecules (MM). Histograms showing (c) Glx and (d) NAA hippocampal concentrations at 6 and
12 months of age, respectively, expressed in nM (N = 12). (e) Results from HPLC on extracellular glutamate hippocampal concentrations at 6 and
12 months of age of Non-Tg and 3×Tg-AD mice. (f, h) Representative western blots for glutamate transporter 1 (GLT-1) and glutamine synthetase
(GS) proteins at 6 and 12 months of age, and (g, i) densitometric analyses normalized with β-actin used as loading controls (N = 3, in triplicate).
Results are expressed as percentage of control (Non-Tg/placebo groups). Data are presented as means ± SEM. Statistical analysis was performed by
two-way ANOVA followed by Bonferroni’s multiple-comparison test (*p < 0.05; **p < 0.01; ***p < 0.001)
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which is already licensed for use in humans, displays a
high tolerability and safety profile and would be an ideal
candidate for long-term use lasting several years, as
potential AD treatments require.
Summarizing, our data suggest that um-PEA exerts a
robust therapeutic effect in a transgenic mouse model
(3×Tg-AD) of AD, since it ameliorates both cognitive
deficits and a range of neuropathological features. Despite
the limits of our preclinical experimental study and
avoiding any simplistic extrapolation of data from the
animal model to the human condition, the results of this
research suggest that um-PEA demonstrates considerable
potential to have an impact on the progression of AD.
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